Pancreatic cancer, known as the king of cancer, was diagnosed with pancreatic ductal adenocarcinoma in approximately 496,000 people worldwide in 2020 and is the seventh leading cause of cancer-related deaths.
OxSonics Therapeutics, announces that first-in-human clinical data demonstrated that SonoTran® is safe and well-tolerated, with consistent Particle activation observed and mapped using OxSonics’ proprietary “see-as-you-treat” technology.